Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Dexmethylphenidate.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

2.

Dexmethylphenidate Extended Release-Associated Orofacial Dyskinesia in an Adolescent with Autism Spectrum Disorder After Prolonged Use.

Baweja R, Mills S, Waxmonsky J.

J Child Adolesc Psychopharmacol. 2018 Jul/Aug;28(6):423-424. doi: 10.1089/cap.2018.0034. Epub 2018 May 21. No abstract available.

PMID:
29781724
3.
4.

Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.

Zhu HJ, Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS.

J Clin Psychopharmacol. 2017 Aug;37(4):419-428. doi: 10.1097/JCP.0000000000000721.

5.

Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.

Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF, Scarpato J, Smith T, Sprod LK, Miller SM.

JAMA Oncol. 2017 Jul 1;3(7):961-968. doi: 10.1001/jamaoncol.2016.6914. Review.

6.

Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.

Cortese S, Adamo N, Mohr-Jensen C, Hayes AJ, Bhatti S, Carucci S, Del Giovane C, Atkinson LZ, Banaschewski T, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A, Coghill D; European ADHD Guidelines Group (EAGG).

BMJ Open. 2017 Jan 10;7(1):e013967. doi: 10.1136/bmjopen-2016-013967.

7.

Development of a refill pattern method to measure polypharmacy in administrative claims databases.

Liu X, Kubilis P, Bussing R, Winterstein AG.

Pharmacoepidemiol Drug Saf. 2016 Dec;25(12):1407-1413. doi: 10.1002/pds.4082. Epub 2016 Aug 16.

PMID:
27528378
8.

Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.

Sayer GR, McGough JJ, Levitt J, Cowen J, Sturm A, Castelo E, McCracken JT.

J Child Adolesc Psychopharmacol. 2016 Dec;26(10):882-888. Epub 2016 Aug 2.

9.

Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.

Patrick KS, Straughn AB.

Drug Metab Dispos. 2016 Mar;44(3):418-21. doi: 10.1124/dmd.115.067975. Epub 2016 Jan 4.

10.

Comparative efficacy, acceptability, and tolerability of dexmethylphenidate versus placebo in child and adolescent ADHD: a meta-analysis of randomized controlled trials.

Maneeton N, Maneeton B, Woottiluk P, Suttajit S, Likhitsathian S, Charnsil C, Srisurapanont M.

Neuropsychiatr Dis Treat. 2015 Nov 25;11:2943-52. doi: 10.2147/NDT.S91765. eCollection 2015.

11.

The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.

Perugi G, Vannucchi G.

Expert Opin Pharmacother. 2015;16(14):2193-204. doi: 10.1517/14656566.2015.1079620. Review.

PMID:
26364896
12.

Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder.

Buitelaar J, Asherson P, Soutullo C, Colla M, Adams DH, Tanaka Y, Haynes VS, Escobar R, Upadhyaya H.

Eur Neuropsychopharmacol. 2015 Oct;25(10):1611-21. doi: 10.1016/j.euroneuro.2015.06.003. Epub 2015 Jun 22. Review.

13.

Comparative Ethanol-Induced Potentiation of Stimulatory Responses to Dexmethylphenidate Versus Methylphenidate.

Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Malcolm R.

J Clin Psychopharmacol. 2015 Aug;35(4):464-7. doi: 10.1097/JCP.0000000000000348.

14.

Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.

Patrick KS, Corbin TR, Murphy CE.

J Pharm Sci. 2014 Dec;103(12):3834-3842. doi: 10.1002/jps.24202. Epub 2014 Oct 9. Review.

15.
16.

Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.

Sugrue D, Bogner R, Ehret MJ.

Am J Health Syst Pharm. 2014 Jul 15;71(14):1163-70. doi: 10.2146/ajhp130638. Review.

PMID:
24973373
17.

Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.

Stein MA, Waldman I, Newcorn J, Bishop J, Kittles R, Cook EH Jr.

J Child Adolesc Psychopharmacol. 2014 Jun;24(5):238-44. doi: 10.1089/cap.2013.0102. Epub 2014 May 9.

18.

Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011.

Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS.

Am J Manag Care. 2014 Mar 1;20(3):e90-7.

19.
20.

Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.

Setyawan J, Guérin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.

J Med Econ. 2013 Nov;16(11):1275-89. doi: 10.3111/13696998.2013.839947. Epub 2013 Sep 19.

PMID:
24004347

Supplemental Content

Loading ...
Support Center